CSIMarket
 
Chimerix Inc   (CMRX)
Other Ticker:  
 
 
Price: $1.1000 $-0.05 -4.348%
Day's High: $1.17 Week Perf: -6.78 %
Day's Low: $ 1.10 30 Day Perf: 5.77 %
Volume (M): 224 52 Wk High: $ 1.57
Volume (M$): $ 247 52 Wk Avg: $1.10
Open: $1.16 52 Wk Low: $0.88



 Market Capitalization (Millions $) 97
 Shares Outstanding (Millions) 88
 Employees 181
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -82
 Cash Flow (TTM) (Millions $) 2
 Capital Exp. (TTM) (Millions $) 0

Chimerix Inc
Chimerix Inc is an American biopharmaceutical company that focuses on developing medicines for various viral infections and cancer treatment. The company has been operational since 2002 and is headquartered in Durham, North Carolina.

Chimerix's primary focus is on the development of antiviral therapies for life-threatening viral infections. One of its most notable products is brincidofovir, an antiviral drug that is used to treat cytomegalovirus (CMV). CMV is a viral infection that is prevalent in people with weakened immune systems, such as organ transplant recipients and HIV/AIDS patients.

In addition to CMV, Chimerix is also working on developing therapies for other viral infections such as adenovirus, BK virus, and human papillomavirus (HPV). The company's research in this area involves the use of small molecules to target viral proteins.

Apart from antiviral therapies, Chimerix is also involved in the development of oncology drugs. The company's lead oncology candidate is dociparstat sodium, a drug that targets the heparanase enzyme, which plays a critical role in the development and spread of cancer cells. Dociparstat sodium is being investigated for its potential use in the treatment of acute myeloid leukemia (AML) and multiple myeloma.

The company has also developed a proprietary lipid nanoparticle delivery technology platform, which is being used to enhance the delivery of RNA-based drugs, including gene therapy and gene editing.

As of 2021, Chimerix has a research and development team of over 60 scientists and researchers working in their state-of-the-art facility in Durham. The company's innovative approach to drug development has earned it numerous accolades, including the Frost & Sullivan 2018 Best Practices Award for New Product Innovation.


   Company Address: 2505 Meridian Parkway Durham 27713 NC
   Company Phone Number: 806-1074   Stock Exchange / Ticker: NASDAQ CMRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Chimerix Inc

Serious headline: Chimerix Inc Sees Decrease in Losses During Fourth Quarter of 2023

Chimerix Inc, a major pharmaceutical preparations company, experienced a decrease in their loss per share for the October to December 31, 2023 interval. The loss per share decreased from $-0.22 to $-0.20 compared to the same period the previous year. Additionally, their income per share improved from $-0.27 to -$0.20 from the prior quarter.
However, the company witnessed a sharp decline in revenue during this interval. The revenue dropped from $0.81 million in the same quarter the previous year to $0.00 million, and sequentially from $0.01 million.

Chimerix Inc

Chimerix Inc Faces Catastrophic Plunge in Revenue, Threatening its Future Viability



Chimerix Inc, a major pharmaceutical preparations company, recently reported disastrous financial results for the third quarter of 2023. Revenue plummeted by a staggering -99.966% to just $0.01 million, and the net deficit per share widened to $-0.27 from the same reporting period a year before. As Chimerix Inc prepares to release its next financial report on March 01, 2024, it is crucial to examine the implications of these financial challenges on the company's future.
1. Revenue Decline:
The most alarming aspect of Chimerix Inc's financial report is the steep decline in revenue. Sequentially, revenue tumbled by -57.692% from $0.03 million. This significant reduction warrants concern and raises questions about the company's ability to generate sufficient revenue in the short term.

Chimerix Inc

Chimerix Inc Nosedives in Q2 2023 - Reports 94% Revenue Plunge Amidst Pharmaceutical Industry's Growth

Chimerix Inc is a pharmaceutical company that recently reported its financial results for the most recent fiscal period. Despite facing some challenges, the company showed improvements in various aspects of its business.
In terms of earnings per share (EPS), Chimerix Inc managed to decrease its loss per share from $0.27 a year ago to $0.21 in the most recent fiscal period. Additionally, the company's EPS improved from $0.24 per share in the prior reporting period. These positive results indicate that Chimerix Inc has been able to reduce its losses and make progress towards profitability.

Chimerix Inc

Chimerix Inc's Revenue Soars, Despite Lingering Profitability Challenges

Chimerix Inc, a pharmaceutical company, recently announced that it experienced a significant revenue increase of 1786.667% year-on-year during the financial time-frame ending March 31 2023, with earnings of $0.28 million. However, despite the rise in revenue, the company recorded a net loss of $-0.24. This represents an increased loss compared to the preceding quarter, which recorded a loss of $-0.22 per share, and a significant reduction in revenue by -65.233% from $0.81 million.
During the first quarter of the 2023 earnings season, Chimerix Inc reported a net loss of $-21.372 million, a decrease from the $-24.767 million deficit recorded in the same quarter a year ago. While the company has experienced an impressive revenue increase, it is clear that this has yet to translate into profitability.






 

Chimerix Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com